Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences

SAN DIEGO, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio(®)” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that its data will be presented at the Schweizerische Ophthalmologische Gesellschaft (SOG) Annual Congress being held on August 26-28, 2026, in Lausanne, Switzerland and the 19th Asia-Pacific Vitreo-retina Society (APVRS) Congress being held on August 28-30, 2026, in Gold Coast, Australia.

SOG Presentation Details Session: Free Communications I – Retina Vitreous Title: Results from the Phase 3 Dragon Study of Tinlarebant for Adolescent and Adult Stargardt Disease Presenter: Dr.med. Hoai Viet Tran, FMH, FEBO, Consultant Physician, Head of the Ocular Genetics & Gene Therapy Unit, Department of Ophthalmology, University of Lausanne, Hôpital ophtalmique Jules-Gonin, Fondation Asile des aveugles Date and Time: August 27, 2026, 8:30 – 8:40 p.m. CEST Location: SwissTech Convention Center, EPFL Campus, Lausanne, Switzerland